Brief: Tectonic Therapeutic Announces Favorable Phase 1A Safety
19/09/2024 21:04
Sept 19 (Reuters) - Tectonic Therapeutic Inc TECX.O :
* TECTONIC THERAPEUTIC ANNOUNCES FAVORABLE PHASE 1A SAFETY,
TOLERABILITY AND PK/PD RESULTS FOR LEAD PROGRAM TX45
* TECTONIC THERAPEUTIC INC -TX45 WAS WELL-TOLERATED WITH NO
OBSERVED IMMUNOGENICITY
* TECTONIC THERAPEUTIC INC - TX45 DEMONSTRATED A FAVORABLE
PK/PD
RELATIONSHIP WHICH WAS USED TO IDENTIFY DOSES FOR PHASE 2
CLINICAL TRIAL
* TECTONIC THERAPEUTIC INC -SCREENING FOR PHASE 2 APEX
CLINICAL
TRIAL HAS BEEN INITIATED AND TOPLINE RESULTS ARE ANTICIPATED IN
2026
Source text for Eikon: ID:nGNX1rj78c
Further company coverage: TECX.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on Tectonic Therapeutic
See all newsTectonic Therapeutic Inc reports results for the quarter ended June 30 - Earnings Summary
Tectonic Therapeutic Q2 net loss widens on higher costs
Tectonic Therapeutic Inc expected to post a loss of $1.35 a share - Earnings Preview
Brief: Tectonic Therapeutic Completes Enrollment In Tx45 Apex Phase 2 Clinical Trial In Ph-Hfpef Patients
Tectonic Therapeutic Q1 net loss widens on higher R&D costs